We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · June 23, 2022

Preclinical and Clinical Evaluation of the LRRK2 Inhibitor DNL201 for PD

Science Translational Medicine


Additional Info

Science Translational Medicine
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease
Sci Transl Med 2022 Jun 08;14(648)eabj2658, D Jennings, S Huntwork-Rodriguez, AG Henry, JC Sasaki, R Meisner, D Diaz, H Solanoy, X Wang, E Negrou, VV Bondar, R Ghosh, MT Maloney, NE Propson, Y Zhu, RD Maciuca, L Harris, A Kay, P LeWitt, TA King, D Kern, A Ellenbogen, I Goodman, A Siderowf, J Aldred, O Omidvar, ST Masoud, SS Davis, A Arguello, AA Estrada, J de Vicente, ZK Sweeney, G Astarita, MT Borin, BK Wong, H Wong, H Nguyen, K Scearce-Levie, C Ho, MD Troyer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading